Companies

Lupin, Cipla in Rs 7,000-cr league

Our Bureau Mumbai | Updated on March 12, 2018 Published on May 10, 2012

Ciplagrph





Drugmaker Lupin has catapulted itself into the pharma big league, lunging ahead of Cipla, with both clocking revenues of over Rs 7,000 crore for the year ended March 31, 2012.

“We have come a long way,” Lupin Managing Director, Dr K.K. Sharma said, reminiscing on how the company's turnover was about Rs 1,200 crore, nine years ago.

Lupin's consolidated total income for the year ended March 31 stood at Rs 7,097 crore compared with Rs 5,841 crore in the previous year. Net profit for the year under review was Rs 867 crore, compared with Rs 862 crore last year.

The heartening part of the growth is that it has been “secular” across markets in the US, Europe, Japan and rest of the world, Dr Sharma told Business Line, adding that the company has distributed the risk across markets.

The three months ended March 31, however, saw a dip in net profits, due to reasons including the translational losses caused by a fluctuating rupee, he added.

Lupin consolidated sales increased from Rs 1,556 crore for the quarter ended March 31, 2011, to Rs 1,932 crore in the period under review. Net profit stood at Rs 155 crore for the period under review, down from Rs 227 crore in the corresponding period last year.

Rationalisation at Cipla

Having clocked a total income of Rs 7,074 crore for the year ended March, Cipla said its ongoing process of rationalisation of products and markets would continue. Last year's total income stood at Rs 6,398 crore.

The effort would be to get more value of Cipla's partnerships with overseas companies, Mr S. Radhakrishnan, Cipla's Executive Director told Business Line. Income from operations saw a 10 per cent growth, and PAT crossed Rs 1,100 crore and grew by 17 per cent.

During the fourth quarter ended March 31, income from operations grew by more than 12 per cent, at Rs 1,890 crore for the quarter under review. Net profit grew by 36 per cent in the quarter under review, at Rs 291 crore.

Cipla shares were marginally up on the BSE, at Rs 325, while Lupin shares were down four per cent at Rs 521, on Thursday.

>[email protected]

Published on May 10, 2012
null
This article is closed for comments.
Please Email the Editor